Abstract: The invention concerns an extruded depot form for sustained active substance release, comprising at least one active substance, at least one first compound from the class of biodegradable organic polymers based on lactic acid and/or glycolic acid and at least one second compound from the class of lipids.
Type:
Application
Filed:
September 18, 2020
Publication date:
July 6, 2023
Applicant:
AMW GMBH
Inventors:
Elisabeth RITTER, Alexandra FEUERSINGER, Lukas OLIV, Klaus RADDATZ, Dirk BARTH
Abstract: The invention concerns an extruded depot form for sustained active substance release, comprising at least one active substance and at least one first compound from the class of biodegradable organic polymers based on lactic acid and/or glycolic acid.
Type:
Application
Filed:
September 18, 2020
Publication date:
July 6, 2023
Applicant:
AMW GMBH
Inventors:
Elisabeth RITTER, Alexandra FEUERSINGER, Lukas OLIV, Klaus RADDATZ, Dirk BARTH
Abstract: The present invention concerns a transdermal delivery system (TDS) comprising at least one active ingredient, wherein the active ingredient is in a non-aqueous matrix, and wherein the non-aqueous matrix has a reduced moisture content. Furthermore, the present invention concerns a method for the production of the TDS in accordance with the invention, as well as the use of the TDS in accordance with the invention.
Abstract: The present invention relates to a transdermal delivery system (TDS) comprising at least one dopamine agonist, wherein the at least one dopamine agonist is present in a matrix containing at least one polymer from the class of polybutylene. The present invention also relates to a method for producing the TDS according to the invention and to the use of the TDS according to the invention.
Abstract: The present invention concerns a method for the production of a transdermal delivery system (TDS) comprising at least one active ingredient, wherein the method comprises temperature-conditioning. Furthermore, the present invention concerns a TDS which can be produced by means of the method in accordance with the invention, as well as the use of the TDS in accordance with the invention.
Type:
Application
Filed:
October 19, 2018
Publication date:
September 17, 2020
Applicant:
AMW GMBH
Inventors:
Verena SONNTAG, Martina KESSLER, Hubert KAFFL
Abstract: The invention relates to an extruded depot form for a continuing active substance release, comprising at least one active substance and at least two compounds of the class of substances which can be broken down by lipases. The at least two compounds comprise a low-melting compound and a high-melting compound, and the ratio of the low-melting compound to the high-melting compound ranges from 1:9 to 9:1. The depot form also optionally comprises at least one auxiliary agent for modulating the active substance release, wherein b), or optionally b) and c), constitute at least 60 wt. % of the dry weight of the depot form.
Abstract: The invention concerns a transdermal therapeutic system with a carbamate cholinesterase inhibitor for the treatment of mild to moderate Alzheimer's disease dementia and/or Parkinson's disease dementia.
Type:
Application
Filed:
January 10, 2013
Publication date:
July 11, 2013
Applicants:
AMW GMBH, ALFRED E. TIEFENBACHER (GMBH & CO. KG)
Inventors:
ALFRED E. TIEFENBACHER (GmbH & Co. KG), AMW GmbH